Johnson & Johnson JNJ, +0.49% said Tuesday it had net earnings of $4.132 billion, or $1.70 a share, for the fourth quarter, up from $3.227 billion, or $1.22 a share, in the year-earlier period. Adjusted per-share earnings came to $2.29, just ahead of the $2.28 FactSet consensus. Sales rose to $21.395 billion from $19.939 billion a year ago, also ahead of the $21.022 billion FactSet consensus. By segment, sales at the company’s innovative medicine business, including COVID vaccines, rose 4.8% to $13.722 bil ...

The stock trading graph of Johnson & Johnson is seen on a smartphone screen.Johnson & Johnson on Tuesday reported fourth-quarter earnings and revenue that narrowly edged out Wall Street's expectations as sales in the company's pharmaceutical and medical devices businesses surged.J&J also provided full-year guidance for 2024, forecasting sales of $87.8 billion to $88.6 billion and adjusted earnings of $10.55 to $10.75 per share. Here's what J&J reported for the fourth quarter compared with what Wall Street w ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2023. “Johnson & Johnson’s full year 2023 results reflect the breadth and competitiveness of our business and our relentless focus on delivering for patients,” said Joaquin Duato, Chairman and Chief Executive Officer. “We have entered 2024 from a position of strength, and I am confident in our ability to lead the next wave of health innovation.” Unless otherwise noted, the financia ...

Key PointsWK Kellogg, Newmont and WEC Energy Group are trading at low valuations relative to their earnings potential.If 2024 is a more challenging environment, undervalued and value stocks in general may perform better.Investors can determine if a stock is undervalued by using ratios of book value, earnings and sales to price.5 stocks we like better than Berkshire HathawayFor savvy investors, hunting down undervalued stocks can mean unearthing overlooked stocks with big potential. In any market cycle, unde ...

The closer retirement gets for some people, the more apprehensive they get about finances. It can be nerve-wracking to think about living off of a fixed income. Things can get even more anxiety-producing when considering how to invest your retirement savings.Fortunately, there are ways to invest that can provide income without a huge amount of risk. Are you nearing retirement? These stocks, listed in alphabetical order, are as safe as they come and are worth a look.1. Johnson & JohnsonFew stocks offer as lo ...

If there is one thing income investors hate, it's when a company decides to slash or suspend its dividend. Yes, sometimes the business requires it, but that's cold comfort for those who count on regular and rising payouts. Recently, the leading pharmacy chain Walgreens Boots Alliance (WBA -0.68%) made the difficult decision to decrease its dividend by 48%, much to the dismay of investors.The company's financial position arguably justifies the move, but what about investing in a stock whose underlying busine ...

shih-wei By Valuentum Analysts In common nomenclature for dividend growth investors, a Dividend King is a company that has raised its dividend in each year for the past 50+ years. If you think about what a firm has had to endure to keep raising its payout each year over a half century, the label is quite impressive. Not only have these companies endured savings & loan crises, the dot-com bust, wars, the Great Financial Crisis, and COVID-19 meltdown, but they have thrived over this time period to keep ra ...

Johnson & Johnson (JNJ) will report fourth-quarter and full-year 2023 results on Jan 23, before market open. In the last reported quarter, the company delivered an earnings surprise of 5.56%.Factors to ConsiderJ&J’s Innovative Medicines segment (previously the Pharmaceutical segment) sales are expected to have been driven by higher sales of key products such as Darzalex, Stelara, Tremfya and Erleada due to strong market growth and demand trends.The Zacks Consensus Estimate for Darzalex is pegged at $2.50 bi ...

About this content About Stephen Gunnion Stephen Gunnion is a senior financial journalist and broadcaster at Proactive Investors. He has more than 25 years of experience in television, radio and print media, anchoring on a number of television channels including South Africa's Business Day TV, CNBC Africa and the South African Broadcasting Corporation, where he was the economics editor. He has also worked for Daily Maverick, Bloomberg, the Business Day newspaper and Investors' Chronicle. Read more About ...

BrilliantEye Introduction Johnson & Johnson (NYSE:JNJ) stock undoubtedly occupies a top spot in many individual stock portfolios - and portfolio managers (individual or institutional) can't be blamed - JNJ delivers like clockwork and its long-term performance (30-year return CAGR of 11.8% vs. 10.0% for the S&P 500 (SPY), coupled with its low volatility (five-year beta of just around 0.6, 30-year max. drawdown of 33% vs. 51% for the S&P 500) is truly remarkable. I am no exception to this "rule" as JNJ stock ...